News

Filter

1 to 9 of 206 results

NantWorks and Sorrento enter second collaboration on novel anti-cancer immunotherapies

NantWorks and Sorrento enter second collaboration on novel anti-cancer immunotherapies

17-03-2015

Privately-held NantWorks and Sorrento Therapeutics have entered into a second global collaboration, this…

BiotechnologyLicensingNantworksOncologyResearchSorrento Therapeutics

MultiCell and Oxis Biotech sign antibody-drug conjugate collaboration

MultiCell and Oxis Biotech sign antibody-drug conjugate collaboration

13-03-2015

MultiCell Immunotherapeutics (MCIT), a majority owned subsidiary of MultiCell Technologies, has signed…

BiotechnologyLicensingMultiCell ImmunotherapeuticsMultiCell TechnologiesOncologyOxis BiotechResearch

EMD Serono and Opexa amend deal on MS drug candidate Tcelna

EMD Serono and Opexa amend deal on MS drug candidate Tcelna

09-03-2015

EMD Serono, the US biopharmaceutical division of Germany’s Merck KGaA has amended its agreement with…

BiotechnologyEMD SeronoFinancialLicensingMerck KGaANeurologicalOpexa TherapeuticsResearchTcelna

Spero Therapeutics gains rights to novel anti-infectives developed at HZI

Spero Therapeutics gains rights to novel anti-infectives developed at HZI

06-03-2015

Ascenion, the technology transfer partner of Germany’s Helmholtz Center for Infection Research (HZI),…

Antibiotics and Infectious diseasesBiotechnologyLicensingResearchSpero Therapeutics

Genmab inks DuoBody deal with BioNovion in the field of immuno-oncology

19-02-2015

Danish biotech company Genmab has entered into a co-development and commercialization agreement with…

BioNovionBiotechnologyDuoBodyGenmabImmunologicalsLicensingOncologyResearch

Voyager inks up to $845 million deal with Genzyme on novel CNS products

Voyager inks up to $845 million deal with Genzyme on novel CNS products

12-02-2015

US gene therapy start-up company Voyager Therapeutics has entered into a major strategic collaboration…

BiotechnologyGenzymeLicensingNeurologicalResearchSanofiUSAVoyager Therapeutics

Pfenex soars on Lucentis biosimilar deal with Hospira

Pfenex soars on Lucentis biosimilar deal with Hospira

10-02-2015

Shares of US clinical-stage biotech firm Pfenex leapt 28% to $8.85 in morning trading, after the company…

BiosimilarsBiotechnologyGenentechGlobalHospiraLicensingLucentisNovartisOphthalmicsPF582PfenexResearchRoche

TxCell receives latest 1 million-euro milestone payment in OvaSave license agreement

TxCell receives latest 1 million-euro milestone payment in OvaSave license agreement

29-01-2015

French biotech company TxCell has received the latest 1 million-euro milestone payment ($1.13 million)…

BiotechnologyGastro-intestinalsLicensingOvaSaveResearchTxCell

1 to 9 of 206 results

Back to top